Clinical Trial Update: LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of LBH589 (panobinostat) in adults with advanced solid tumors or cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Solid Tumors

Drugs mentioned

• LBH589 (panobinostat)

Snippet

Sponsor: Novartis | Conditions: Tumors, Cutaneous T-Cell Lymphoma | Phase 1 | Status: COMPLETED